You just read:

LCS Therapeutics and Lucerne Biosciences to Commercialize '813 Patent for Lisdexamfetamine Dimesylate in the Treatment of Binge Eating Disorder

News provided by

LCS Group, LLC

Dec 26, 2014, 06:00 ET